Based on the HBM HLDGS LTD DL-000025 stock forecast from 0 analysts, the average analyst target price for HBM HLDGS LTD DL-000025 is not available over the next 12 months. HBM HLDGS LTD DL-000025’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of HBM HLDGS LTD DL-000025 is Slightly Bullish , which is based on 6 positive signals and 3 negative signals. At the last closing, HBM HLDGS LTD DL-000025’s stock price was EUR 0.14. HBM HLDGS LTD DL-000025’s stock price has changed by +20.54% over the past week, +8.00% over the past month and -10.60% over the last year.
No recent analyst target price found for HBM HLDGS LTD DL-000025
No recent average analyst rating found for HBM HLDGS LTD DL-000025
Company Overview HBM HLDGS LTD DL-000025
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The company has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4; and HBM1020, human monoclonal antibody generated from harbour mice platform targeting B7H7. The company is also developing HBM9378 for the treatment of Asthma; and HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaborations with AstraZeneca, Pfizer, Hualan Genetic Engineering Co., Ltd., Beigene, Ltd., Duality Biotherapetuics, Inc., Mythic Therapeutics, Washington University, Evive Biotech. HBM Holdings Limited was incorporated in 2016 and is based in Suzhou, the People's Republic of China. Read Less
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The company has developed the Harbour Mice Platform, which generates fully human monoclonal...Read More
Frequently Asked Questions About HBM HLDGS LTD DL-000025 (6XY:F) Stock
Stock Target Advisor's fundamental analysis for HBM HLDGS LTD DL-000025's stock is Slightly Bullish .
Unfortunately we do not have enough data on 6XY:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6XY:F's stock to indicate what its average analyst target is.
6XY:F stock's Price/Earning ratio is 4.50.
Our analysis grades 6XY:F stock's Price / Earning ratio at C+. This means that 6XY:F stock's Price/Earning ratio is above 21% of the stocks in the Biotechnology sector in the F exchange.
Based on this 6XY:F may be undervalued for its sector.
The last closing price of 6XY:F's stock was EUR 0.14.
The most recent market capitalization for 6XY:F is EUR 0.12B.
Unfortunately we do not have enough analyst data on 6XY:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains HBM HLDGS LTD DL-000025's stock.
As per our most recent records HBM HLDGS LTD DL-000025 has 182 Employees.
HBM HLDGS LTD DL-000025's registered address is Building A3, Suzhou, China, 215123.
You can get more information about it from HBM HLDGS LTD DL-000025's website at https://www.harbourbiomed.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About HBM HLDGS LTD DL-000025 (6XY:F) Stock
Stock Target Advisor's fundamental analysis for HBM HLDGS LTD DL-000025's stock is Slightly Bullish .
Unfortunately we do not have enough data on 6XY:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6XY:F's stock to indicate what its average analyst target is.
6XY:F stock's Price/Earning ratio is 4.50.
Our analysis grades 6XY:F stock's Price / Earning ratio at C+. This means that 6XY:F stock's Price/Earning ratio is above 21% of the stocks in the Biotechnology sector in the F exchange.
Based on this 6XY:F may be undervalued for its sector.
The last closing price of 6XY:F's stock was EUR 0.14.
The most recent market capitalization for 6XY:F is EUR 0.12B.
Unfortunately we do not have enough analyst data on 6XY:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains HBM HLDGS LTD DL-000025's stock.
As per our most recent records HBM HLDGS LTD DL-000025 has 182 Employees.
HBM HLDGS LTD DL-000025's registered address is Building A3, Suzhou, China, 215123.
You can get more information about it from HBM HLDGS LTD DL-000025's website at https://www.harbourbiomed.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 6XY:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
